Bausch + Lomb will pair BHVI's novel contact lens design with its leading contact lens technologies.
This is for the reduction of pediatric myopia progression In children ages 3-12.
Bausch + Lomb - NewCo will be a publicly traded company.
NOV03 showed statistically significant and clinically meaningful improvement in a variety of symptoms over the entire duration of the trial.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
